Journal
DRUG DISCOVERY TODAY
Volume 24, Issue 1, Pages 334-341Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.10.001
Keywords
-
Categories
Funding
- CONACyT [271307, 272968]
- Centro de Investigacion y Asistencia en Tecnologia y Diseno del Estado de Jalisco
Ask authors/readers for more resources
Human induced pluripotent stem cells (hiPSCs) enable in vitro high-throughput pharmacological screening assays of diseased tissue. Together with recent genome-wide association studies (GWAS), hiPSCs enable the identification of key mutations for the development of effective treatments based on precise drugs. In concert with CRISPR/Cas9 systems, hiPSC technology can reveal therapeutic targets in metabolic disorders. The ex vivo CRISPR correction of autologous patient-derived hiPSCs has led to the development of replacement cell therapies, providing better patient prognoses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available